Table 2.
Multivariate analysis of possible influence factors on PFS and OS
| Factor | PFS | OS | ||
|---|---|---|---|---|
| HR (95% CI) | P‐value | HR (95% CI) | P‐value | |
| Age | 1.15 (1.04; 1.28) | 0.01 | 1.35 (1.17;1.56) | <0.001 |
| Year of ASCT | 1.01 (0.99; 1.03) | 0.24 | 1.02 (0.99;1.05) | 0.21 |
| MM type (reference: IgG) | ||||
| IgA | 1.06 (0.84; 1.34) | 0.61 | 1.02 (0.77;1.36) | 0.89 |
| IgD | 0.70 (0.28; 1.72) | 0.44 | 0.93 (0.34;2.55) | 0.89 |
| Bence‐Jones | 1.05 (0.83; 1.33) | 0.67 | 1.00 (0.74;1.35) | 0.99 |
| ISS stage (reference: 1) | ||||
| 2 | 1.05 (0.84; 1.30) | 0.69 | 1.04 (0.79;1.35) | 0.80 |
| 3 | 1.30 (0.98; 1.73) | 0.07 | 1.34 (0.94;1.91) | 0.10 |
| Laboratory values at diagnosis | ||||
| Hemoglobin < 10 g/dL | 1.09 (0.87; 1.37) | 0.48 | 0.92 (0.69;1.24) | 0.60 |
| Thrombocytes < 150.000/μL | 1.48 (1.07; 2.04) | 0.02 | 1.67 (1.10;2.52) | 0.02 |
| Creatinine ≥ 2 mg/dL | 0.99 (0.72; 1.38) | 0.97 | 1.32 (0.89;1.96) | 0.17 |
| LDH > upper limit of normal | 1.11 (0.87; 1.43) | 0.40 | 1.28 (0.94;1.74) | 0.11 |
| CR after ASCT | 0.69 (0.52; 0.93) | 0.01 | 0.82 (0.57;1.17) | 0.27 |
| Novel agent‐based induction | 0.58 (0.45; 0.74) | <0.001 | 0.48 (0.35;0.67) | <0.001 |
| Tandem ASCT | 0.93 (0.75; 1.14) | 0.46 | 0.80 (0.61;1.04) | 0.10 |
| Maintenance therapy | 0.53 (0.42; 0.65) | <0.001 | 0.48 (0.37;0.63) | <0.001 |